Solentim & Valitacell announce collaboration

Integrating Valitacell’s in-line analytical profiling technologies with Solentim’s innovative image-driven liquid handling and cell measurement technology will transform workflows, creating a streamlined platform which synergises attribute-rich profiling of clones and earlier decision making.

E-mail Address
[email protected]

Aaron Figg, Director
"We strive to support our customers in developing more and better biopharmaceuticals to treat patients. By continually innovating to create unique and unrivalled technologies, we bring practical solutions to the problems of the drug discovery and development process"

Optimising workflows

We provide solutions for customers working across cell line development:

Novel Biotherapeutics

Isolate, screen and characterise attributes for clones producing novel recombinant proteins e.g. monoclonal antibodies or therapeutic proteins for rare diseases

Read More >

Biosimilars and Biobetters

Generate stable cell lines to create equivalents (Biosimilars) or improved versions (Biobetters) of existing blockbuster therapeutic antibodies for which the patent has, or will shortly, expire

Read More >

Gene Editing & Cell Engineering

Optimise your drug discovery process using targeted gene editing to create stable cell lines as cellular reagents, for use in target validation, functional genomics and disease modelling

Read More >

Gene Therapy & CAR-T

Develop new, stable, producer cell lines manufacturing viruses to subsequently infect target cells of patients

Read More >

Antibody Discovery

Discover novel antibody sequences and produce diverse antibodies; using hybridomas and B cells to create new therapies and diagnostic antibodies

Read More >

VIEW OUR WEBINAR

"How a Top-5 Pharma Doubled the Speed of Cell Line Development"

Latest News

Valitacell and Solentim announce collaboration to accelerate discovery and development of biologic drugs and advanced cell therapies

  21st February 2019: Valitacell, a biotechnology company transforming cell-based manufacturing, and Solentim, a global leader in cell line development instrumentation, today announced a new collaboration to enable earlier identification

Solentim to Present and Exhibit at the ELRIG “CRISPR in Drug Discovery 2019” Conference in Oxford, UK

NEWS – Bournemouth, 11th February 2019: Solentim, a global leader in cell line development instrumentation, is pleased to announce they will be attending the ELRIG CRISPR in Drug Discovery 2019: From

Collaboration: changing CLD practices

In January 2019 Solentim, a global leader in cell line development (CLD) instrumentation, and bioengineering company ATUM, announced a technology partnering and collaboration agreement to enable rapid, high expression, stable cell

Solentim and ATUM announce technology collaboration to enable rapid, high expression, stable cell line development

NEWS – Bournemouth, UK – 14th January 2019: Solentim, a global leader in cell line development instrumentation, and bioengineering company ATUM, today announced a technology partnering and collaboration agreement. This

Solentim Strengthens Team | Claire Richards appointed Head of Biological Science

NEWS – Bournemouth, UK – 10th January 2019: Solentim, the innovator and leader in Cell Line Development instrumentation, is pleased to announce the appointment of Claire Richards as their new

Solentim exhibiting this January at PepTalk in San Diego, CA

NEWS - Bournemouth, UK – 3rd January 2019: Solentim, the innovator and leader in Cell Line Development instrumentation, is pleased to announce they will be exhibiting at the Annual PepTalk

Finding the right balance: digital biology versus smart, transformative automation

In this latest blog by Solentim’s Dr Ian Taylor, the advent of digital biology is discussed. This is compared and contrasted with smarter automation, transformative new biology and better control

Why is a clonally pure cell line so important in CRISPR research?

Never far from scientific and mainstream news, CRISPR is regularly hailed as one of the most important scientific discoveries of our time. With potential applications across wide-ranging fields from medicine

Solentim Wins Place in Deloitte UK Technology Fast 50

Aaron Figg & Ian Taylor at the Deloitte UK Technology Fast 50 Solentim named as one of the top 50 fastest growing UK technologies companies of

Solentim Wins Two Queen’s Awards for Enterprise

Aaron Figg, Dave Elverd, Mr (Ian) Angus Campbell (Her Majesty’s Lord-Lieutenant of Dorset), Ian Taylor, Sky Jiang Solentim’s business excellence and expertise in cell line development